Technology evaluation: MRA, Chugai
journal contribution
posted on 2023-05-26, 15:59 authored by Ding, C, Jones, GChugai, the Japanese subsidiary of Roche, is developing a humanized anti-interleukin (IL)-6 receptor monoclonal antibody MRA for the potential treatment of multiple myeloma, rheumatoid arthritis, Crohn's disease and other IL-6-related disorders. MRA is currently undergoing phase II clinical trials for these indications.
History
Publication title
Current Opinion in Molecular TherapeuticsVolume
5Article number
1Number
1Pagination
64-69ISSN
1464-8431Publication status
- Published
Repository Status
- Open
Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC